drugset / Trial / NCT05662865
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
NaSequentialOpen-labelBasic science
Summary
The purpose of this study is to help us better understand how plasma ketones respond to a low-carb diet when combined with an SGLT2 inhibitor.
Timeline
- Start
- 2023-03-16
- Primary completion
- 2024-07-23
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ertugliflozin | Unknown | 15 mg | — |
Indications
No indication recorded.